Please try another search
CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two gene therapy candidates, including CG01, which is in preclinical studies for the treatment of epilepsy and biodistribution and toxicology studies; and CGT2 for the treatment of lipodystrophy. The company has a licensing and collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions; and with Spark Therapeutics to develop adeno-associated virus (AAV) based gene therapies. CombiGene AB (publ) was founded in 1999 and is headquartered in Lidingö, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Peter Nilsson | 52 | 2014 | Independent Director |
Margitta Seeck | - | - | Member of Scientific Advisory Board |
Annamaria Vezzani | - | - | Member of Scientific Advisory Board |
Gunilla Lundmark | 60 | 2021 | Independent Director |
Per Lundin | 40 | 2020 | Independent Director |
Jonas Ekblom | 58 | 2020 | Independent Chairman of the Board |
Malin Almgren | 47 | 2023 | Independent Director |
Lars Arendt-Nielsen | - | 2023 | Member of Scientific Advisory Board |
Andrew S.C. Rice | - | 2023 | Member of Scientific Advisory Board |
David Bennett | - | 2023 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review